

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.

8002-059

APPLICATION NO.

09/645,415

APPLICANT

Bermudes et al.

FILING DATE

August 24, 2000

GROUP

1632

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
RRS	FN	5,705,151	1/6/98	Dow et al.			
	FO	6,251,406	6/26/01	Haefliger et al.			
	FP	2001/0029043	10/11/01	Haefliger et al.			
RRS	FQ	2001/0006642	7/5/01	Steidler et al.			

RECEIVED

SEP 03 2002

TECH CENTER 1600/2900

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	FR	WO 02/20809	3/14/02	PCT				

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

RRS	FS	Anderson WF, 2001, "Recombinant DNA Advisory Committee Meeting on Issues of Concern to IBCs", Human Gene Therapy 12(12):1594-1596
	FT	Darji et al., 1997, "Oral Somatic Transgene Vaccine Using Attenuated S. typhimurium", Cell 91:765-775
	FU	MacEwen et al., "Genetically Modified Salmonella for Canine Cancer: a Phase I Study", Abstract 82:
	FV	Mier et al., 2001, "Phase I trial of a Live, Attenuated Salmonella Typhimurium (VNP20009) Administered by Direct Intra-Tumoral (IT) Injection", Proc Am. Soc. Clin. Oncol. 20:29 Abstract.
	FW	Paglia et al., "Gene Transfer in Dendritic Cells, Induced by Oral DNA Vaccination With S. Typhimurium, Results in Protective Immunity against a Murine Fibrosarcoma", Blood 92:3172-3176
	FX	Sizemore et al., 1995, "Attenuated Shigella as a DNA Delivery Vehicle for DNA Mediated Immunization", Science 270:299-302
	FY	Tacket CO, 1992, "Comparison of the Safety and Immunogenicity of Δ aroC Δ aro D and Δ cya Δ crp Salmonella typhi Strains in Adult Volunteers", Infect Immun. 60:536-541.
	FZ	Tacket CO, 1997, "Safety of live oral Salmonella typhi vaccine strains with deletions in htrA and aroC aroD and immune response in humans", Infect Immun. 65(2):452-6.
	GA	Tacket CO, 2000, "Phase 2 clinical trial of attenuated Salmonella enterica serovar typhi oral live vector vaccine CVD 908-htrA in U.S. volunteers", Infect Immun.;68(3):1196-201.
	GB	Toso et al., 2002, "Phase 1 Study of the Intravenous Administration of Attenuated Salmonella Typhimurium to Patients with Metastatic Melanoma", J. of Clin. Oncol. 20:142-152
RRS	GC	Urishima et al., 2000, "An Oral Cd 40 ligand gene therapy against lymphoma using attenuated Salmonella typhimurium", Blood 95:1258-1263

EXAMINER

RRS

DATE CONSIDERED

9/3/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Express Mail No.: EL 477 032 632 US

RECEIVED
NOV 29 2001
TECHNICAL CENTER 16001900

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.

8002-059

APPLICATION NO.

09/645,413

APPLICANT

Bermudes et al.

FILING DATE

August 24, 2000

GROUP

1614

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
RMS	FA WO 00/09733	2/24/00	PCT				

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

RMS	FB	Paglia et al., 2000, "In vivo correction of genetic defects of monocyte/macrophages using attenuated Salmonella as oral vectors for targeted gene delivery", Gene Therapy 7:1725-1730


EXAMINER

RMS

DATE CONSIDERED

5/3/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Express Mail No.: **EL 477 033 690 US**

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)					ATTY. DOCKET NO. 8002-059		APPLICATION NO. 09/645,415	
					APPLICANT Bermudes et al.			
					FILING DATE August 24, 2000		GROUP 1632	
U.S. PATENT DOCUMENTS								
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
FOREIGN PATENT DOCUMENTS								
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO	
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)								
RM	FC	Chatfield et al., 1992, "Use of the nirB promoter to direct the stable expression of heterologous antigens in Salmonella oral vaccine strains: development of a single-dose oral tetanus vaccine", Biotechnology (N Y). 10(8):888-92.						
	FD	Chatfield et al, 1992, "Construction of a genetically defined Salmonella typhi Ty2 aroA, aroC mutant for the engineering of a candidate oral typhoid-tetanus vaccine", Vaccine. 10(1):53-60.						
	FE	Curtiss et al, 1989, "Selective delivery of antigens by recombinant bacteria", Curr Top Microbiol Immunol.146:35-49.						
	FF	Gill et al., 1996, "A malignant pleural effusion infected with Salmonella enteritidis", Thorax. 51(1):104-5.						
	FG	Gonzalez et al., 1994, "Salmonella typhi vaccine strain CVD 908 expressing the circumsporozoite protein of Plasmodium falciparum: strain construction and safety and immunogenicity in humans", J Infect Dis. 169(4):927-31.						
	FH	Hohmann et al, 1996, "phoP/phoQ-deleted Salmonella typhi (Ty800) is a safe and immunogenic single-dose typhoid fever vaccine in volunteers", J Infect Dis. 173(6):1408-14.						
	FI	Levine et al., 1987, " Safety, infectivity, immunogenicity, and in vivo stability of two attenuated auxotrophic mutant strains of Salmonella typhi, 541Ty and 543Ty, as live oral vaccines in humans", J Clin Invest. 79(3):888-902.						
	FJ	Saltzman et al., 1997, "Patterns of hepatic and splenic colonization by an attenuated strain of Salmonella typhimurium containing the gene for human interleukin-2: a novel anti-tumor agent", Cancer Biother Radiopharm 12:37-45.						
	FK	Tacket et al., 1997, " Volunteer studies investigating the safety and efficacy of live oral El Tor Vibrio cholerae O1 vaccine strain CVD 111", Am J Trop Med Hyg. 56(5):533-7.						
	FL	Wolfe et al., 1971, "Salmonellosis in patients with neoplastic disease. A review of 100 episodes at Memorial Cancer Center over a 13-year period", Arch Intern Med. 128(4):546-54.						
RM	FM	Zheng et al., 2000, " Tumor amplified protein expression therapy: Salmonella as a tumor-selective protein delivery vector", Oncol Res. 12(3):127-35.						
EXAMINER RM				DATE CONSIDERED 5/3/03				
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.								